Cerecor Turns The LIGHT Back On As Avalo, With PRV Haul In Sight
Anti-LIGHT Focus On IBD Expanded To COVID-19 ARDS
The former Cerecor boasts four pipeline assets that could yield US FDA priority review vouchers. Having divested CNS assets, the renamed firm will focus on IBD with first-in-class anti-LIGHT candidate, plus immunology and rare diseases.
